Synairgen reports positive Phase II asthma trial data
The study investigated SNG001 in patients representing mild-moderate through to severe asthmatics, who caught a cold, and was well tolerated. The difficult to treat asthma patient catergory were
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.